BioTime Co-CEO Dr. Michael D. West to Deliver Plenary Presentation on the Field of Induced Tissue Regeneration at World Stem ...
December 08 2016 - 11:36AM
Business Wire
Presentation Will Describe the Future of Aging
Research and iTRTM, an Emerging Area of Research from BioTime
Dr. West to also Serve on Panel: “Unleashing
Regenerative Medicine to Extend the Healthy Lifespan”
BioTime, Inc. (NYSE MKT: BTX), a clinical-stage
biotechnology company developing and commercializing products
addressing degenerative diseases, today announced that Co-Chief
Executive Officer Michael D. West, Ph.D., is delivering a Plenary
Presentation at the World Stem Cell Summit at the Palm Beach County
Convention Center in West Palm Beach, Florida.
In Dr. West’s presentation, “The Future of Human Aging:
Implications of Induced Tissue Regeneration,” he will put in
perspective his previous work on the immortalizing enzyme
designated telomerase, pluripotent stem cell and reprogramming
technology, and the emerging field of induced tissue regeneration
(iTRTM) for future interventions in the biology of human aging.
BioTime, together with its collaborator Insilico Medicine,
previously announced a collaboration on an artificial intelligence
(AI)-driven resource designed to facilitate the discovery of
iTR-based treatments that could enable the body to repair tissue
damage, without scarring. In his presentation, Dr. West will
describe the biological basis of this new technology, being led by
BioTime.
Dr. West will deliver the presentation on Thursday, December 8,
from 4:15 p.m. to 5:15 p.m. EST in the Grand Ballroom of the Palm
Beach County Convention Center. It will be live-streamed on the
World Stem Cell Summit website and posted to BioTime’s YouTube
channel in the days following the event.
Additionally, Dr. West will serve on a panel, “Unleashing
Regenerative Medicine to Extend the Healthy Lifespan: Technological
Issues and Commercial Opportunities,” on December 8 at 11:00 a.m.
EST.
About BioTime
BioTime, Inc. is a clinical-stage biotechnology company focused
on developing and commercializing novel therapies developed from
what the company believes to be the world’s premier collection of
pluripotent cell assets. The foundation of BioTime’s core
therapeutic technology platform is pluripotent cells that are
capable of becoming any of the cell types in the human body.
Pluripotent cells have potential application in many areas of
medicine with large unmet patient needs, including various
age-related degenerative diseases and degenerative conditions for
which there presently are no cures. Unlike pharmaceuticals that
require a molecular target, therapeutic strategies based on the use
of pluripotent cells are generally aimed at regenerating or
replacing affected cells and tissues, and therefore may have
broader applicability than pharmaceutical products.
In addition to the development of therapeutics, BioTime’s
research and other activities have resulted, over time, in the
creation of other subsidiaries that address other non-therapeutic
market opportunities such as cancer diagnostics, drug development
and cell research products, and mobile health software
applications.
BioTime common stock is traded on the NYSE MKT and TASE under
the symbol BTX. For more information, please visit
www.biotimeinc.com or connect with the company on Twitter,
LinkedIn, Facebook, YouTube, and Google+.
To receive ongoing BioTime corporate communications, please
click on the following link to join our email alert list:
http://news.biotimeinc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161208005838/en/
Investor Contact:EVC Group, Inc.Matt Haines,
917-733-9297mhaines@evcgroup.comorMedia Contact:Gotham
Communications, LLCBill Douglass,
646-504-0890bill@gothamcomm.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Sep 2023 to Sep 2024